{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:37:23Z","timestamp":1773081443630,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejca.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T17:20:35Z","timestamp":1618334435000},"page":"105-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4935-4670","authenticated-orcid":false,"given":"Mary-Ann","family":"El Sharouni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelien E.","family":"Laeijendecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karijn PM.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjen J.","family":"Witkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vigf\u00fas","family":"Sigurdsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-2745","authenticated-orcid":false,"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla H.","family":"van Gils","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willeke AM.","family":"Blokx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2021.03.001_bib1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.03.001_bib2","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.ejca.2021.03.001_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-018-0048-5","article-title":"The new era of adjuvant therapies for melanoma","volume":"15","author":"Eggermont","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2021.03.001_bib4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2021.03.001_bib5","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2021.03.001_bib6","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.03.001_bib7","author":"FDA"},{"issue":"9","key":"10.1016\/j.ejca.2021.03.001_bib8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/00000478-200309000-00002","article-title":"Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy","volume":"27","author":"Li","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ejca.2021.03.001_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.0.CO;2-S","article-title":"Detection of microscopic melanoma metastases in sentinel lymph nodes","volume":"86","author":"Yu","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2021.03.001_bib10","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.1998.16.6.2253","article-title":"Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma","volume":"16","author":"Gershenwald","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.03.001_bib11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0b013e3181855718","article-title":"Regional recurrence after negative sentinel lymph node biopsy for melanoma","volume":"248","author":"Carlson","year":"2008","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ejca.2021.03.001_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archsurg.134.4.381","article-title":"Outcome of patients with melanoma and histologically negative sentinel lymph nodes","volume":"134","author":"Gadd","year":"1999","journal-title":"Arch Surg"},{"issue":"12","key":"10.1016\/j.ejca.2021.03.001_bib13","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1245\/s10434-006-9066-0","article-title":"Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma","volume":"13","author":"Nowecki","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.03.001_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1590\/abd1806-4841.20187312","article-title":"Complete lymphadenectomy following positive sentinel lymph node biopsy in cutaneous melanoma: a critical review","volume":"93","author":"Eiger","year":"2018","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2021.03.001_bib15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/jcp.2003.011742","article-title":"Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry","volume":"57","author":"Gietema","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ejca.2021.03.001_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/jso.26095","article-title":"Challenges in sentinel node pathology in the era of adjuvant treatment","author":"Franke","year":"2020","journal-title":"The Journal of Surgical Oncology"},{"issue":"12","key":"10.1016\/j.ejca.2021.03.001_bib17","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.03.001_bib18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/cancers12041003","article-title":"Healthcare costs of metastatic cutaneous melanoma in the era of immunotherapeutic and targeted drugs","volume":"12","author":"Leeneman","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2021.03.001_bib19","first-page":"19","article-title":"Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data etwork and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"key":"10.1016\/j.ejca.2021.03.001_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.03.010","article-title":"An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma","volume":"114","author":"Cook","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2021.03.001_bib21","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1245\/s10434-019-07204-2","article-title":"Trends in sentinel lymph node biopsy enactment for cutaneous melanoma","volume":"26","author":"El Sharouni","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.03.001_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1245\/s10434-018-6348-2","article-title":"Predictors for use of sentinel node biopsy and the association with improved survival in melanoma patients who have nodal staging","volume":"25","author":"Murtha","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.03.001_bib23","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"ESMO Guidelines Committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.03.001_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.03.001_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijscr.2016.10.040","article-title":"Capsular nevus versus metastatic malignant melanoma - a diagnostic dilemma","volume":"29","author":"Davis","year":"2016","journal-title":"Int J Surg Case Rep"},{"issue":"10","key":"10.1016\/j.ejca.2021.03.001_bib26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/DAD.0000000000001645","article-title":"Three types of nodal melanocytic nevi in sentinel lymph nodes of patients with melanoma: pitfalls, immunohistochemistry, and a review of the literature","volume":"42","author":"Gonzalez-Farre","year":"2020","journal-title":"Am J Dermatopathol"},{"issue":"9","key":"10.1016\/j.ejca.2021.03.001_bib27","doi-asserted-by":"crossref","first-page":"153105","DOI":"10.1016\/j.prp.2020.153105","article-title":"The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma","volume":"216","author":"See","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"4","key":"10.1016\/j.ejca.2021.03.001_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/PAS.0000000000001393","article-title":"Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma","volume":"44","author":"Lezcano","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ejca.2021.03.001_bib29","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/00000478-200210000-00012","article-title":"Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma","volume":"26","author":"Lohmann","year":"2002","journal-title":"Am J Surg Pathol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:02Z","timestamp":1760733062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921001398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":29,"alternative-id":["S0959804921001398"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739934387.793591602","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}